We Detect Autoimmune
Signals Early
Protthera develops a breakthrough blood test for early detection of autoimmune pregnancy risk. Transforming unexplained infertility into a manageable medical condition.
The Hidden Threat in
Pregnancy Loss
Up to 2-5% of women suffer from recurrent miscarriages driven by "alloimmune rejection" — a critical condition where the mother’s immune system mistakenly identifies the pregnancy as a foreign threat and attacks it.
Standard prenatal and diagnostic tests completely miss this. They focus strictly on the baby’s DNA or detect protein markers when it is already too late. They fail to screen the mother’s active immune response on time.
Standard DNA Failure
Legacy diagnostic methods evaluate genetic factors or late markers but remain completely blind to pre-symptomatic maternal immune hostility.
$10k – $20k
Average financial loss per patient on failed, blind IVF cycles that could have been prevented with proper immune screening.
Severe Trauma
Unexplained infertility causes deep psychological devastation for parents.
How It Works:
Predicting Rejection Before It Starts
Protthera replaces diagnostic uncertainty with precise immune screening, identifying hidden autoimmune risks before symptoms appear.
Simple Blood Draw
Raw biological sample collection. 100% non-invasive protocol with zero need for painful tissue biopsies.
Discover CICs
By combining gel electrophoresis with advanced mass spectrometry, Protthera not only detects autoimmune activity from blood samples but also determines which organ is affected and how far the condition has progressed
Improve Outcomes
Protthera develops a machine learning platform that identifies circulating immune complex (CIC) patterns linked to trophoblast rejection. By detecting immune risks at the pre-symptomatic stage, we turn unexplained infertility into a manageable medical condition.
Unmatched Precision,
Fraction of the Cost
Instead of searching for isolated markers, Protthera analyzes the full proteomic landscape of the immune system. By pairing high-resolution gel electrophoresis with our proprietary machine learning platform, we cross-reference complex protein signatures against a growing, specialized database to identify and classify specific autoimmune conditions with a high precision.
Direct cost reduction compared to traditional screening tools.
Faster diagnostic timeline for clinicians to define target therapy protocols.
High Accuracy vs Legacy
Protthera delivers ultra-high specificity and sensitivity that legacy ELISA methodologies simply cannot match.
Pregnancy is Only
The Beginning
The same technology we use to analyse autoimmune pregnancy loss can detect over 250+ autoimmune and immune-mediated conditions before clinical symptoms even appear.
"Once we identify the molecular signature for one condition, our predictive database grows exponentially."
We are moving global healthcare from reactive, late-stage treatment to proactive, precision prevention.
Pregnancy Risk
Alloimmune rejection screening.
Neurodegenerative
Early screening pattern detection for Multiple Sclerosis.
Systemic
Identifying early pre-symptomatic patterns for Rheumatoid Arthritis and Systemic Lupus Erythematosus risks.
Autoimmune diseases targeted for scaling
Future & Roadmap
Our immediate R&D milestones focused on clinical validation, AI database scaling, and market entry pipelines.
60-Patient Pilot
Completion of our first 60-patient clinical pilot aiming at a strict target of >90% test accuracy.
ML Model Expansion
Training and refining our ML pattern recognition database on specific pregnancy loss signals.
LOI Deployment
Securing signed Letters of Intent (LOI) with major regional laboratory and institutions for further development and commercial deployment.
Meet Our Team
A powerful synergy of clinical innovation, biochemistry, machine learning, and international corporate management.
Anton Gakhovitch
CEO10 years in project management, 4 years as CBDO, and 4 years specialized in data analysis.
Oleg Darashkevich, PhD
Chief Scientific officer56+ years of distinguished experience in clinical cardiology and medical innovations.
Maksim Navakouski, PhD
Lead scientist23 years of deep general biochemistry research and laboratory expertise.
Nadezda Akmanova
Chief Financial OfficerExperienced CFO with a solid 24-year history of leading operations in the finance industry.
Miroslav Benčo, PhD
CTO, ML & Pattern Recognition20 years of core expertise in machine learning and advanced pattern recognition systems.
Mariya Nasledysheva
Management & Comms13 years of leadership in cross-cultural communication and strategic operations.
Key Scientific & Innovation Advisors
Full Professor at the Faculty of Electrical Engineering and former rector of the University of Zilina. Extensive leadership experience in European research, ICT, intelligent transportation systems, and innovation programmes.
Research leader in applied mechanical engineering, digital design, technical innovation, and technology transfer. Extensive experience in industrial R&D, competitiveness analysis, advanced materials, and manufacturing systems.
Strategic Advisors:
Academic & Clinical Partners
We collaborate with leading European research institutes and medical facilities to conduct clinical validation and scale our proteomic database.
Gynecological Clinic
SlovakiaPrimary clinical validation venue for patient group trials and sample monitoring protocols.
Mass Spectrometry Laboratory
Institute of Biochemistry and Biophysics, PolandCore infrastructure partner for advanced proteomic environment analysis and screening mapping.
University of Zilina
SlovakiaAcademic research collaboration focused on machine learning algorithms and informational technologies.